-
公开(公告)号：US20220257547A1
公开(公告)日：2022-08-18
申请号：US17732761
申请日：2022-04-29
发明人： Anke Stroyer , Carmen Lobback , Peter Serno , Philipp Rubenbauer , Kai Lovis , Heiko Schirmer , Danja Grossbach , Donald Bierer , Britta Olenik , Tia Jacobs , Julia Küsel
摘要： The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
-
公开(公告)号：US20210113504A1
公开(公告)日：2021-04-22
申请号：US17132765
申请日：2020-12-23
发明人： Anke Stroyer , Carmen Lobback , Peter Serno , Philipp Rubenbauer , Kai Lovis , Heiko Schirmer , Danja Grossbach , Donald Bierer , Britta Olenik , Tia Jacobs , Julia Küsel
摘要： The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
-
公开(公告)号：US09655887B2
公开(公告)日：2017-05-23
申请号：US14893508
申请日：2014-05-16
发明人： Bernhard Lindenthal , Nico Bräuer , Peter Serno , Andrea Rotgeri , Ulrike Fuhrmann , Bernd Buchmann , Anne Mengel , Ulrike Röhn , Antonius Ter Laak
IPC分类号： C07D401/06 , C07D401/14 , C07D403/06 , C07D403/14 , A61K31/416 , A61K31/4439 , A61K31/454 , A61K31/196 , A61K31/405 , A61K31/5415 , A61K31/18 , A61K31/192 , A61K31/365 , A61K31/407 , A61K31/42 , A61K31/444 , A61K31/4545 , A61K31/5377 , A61K31/542 , A61K31/635
CPC分类号： A61K31/454 , A61K31/18 , A61K31/192 , A61K31/196 , A61K31/365 , A61K31/405 , A61K31/407 , A61K31/416 , A61K31/42 , A61K31/444 , A61K31/4545 , A61K31/5377 , A61K31/5415 , A61K31/542 , A61K31/635 , A61K2300/00
摘要： The invention relates to a pharmaceutical composition for non-hormonal, on-demand contraception and to processes for preparing this pharmaceutical composition. The latter comprises 2H-indazole as novel EP2 receptor antagonists in combination with COX inhibitors. The invention furthermore provides a method for non-hormonal female-controlled on-demand contraception where a pharmaceutical composition comprising EP2 receptor antagonists in combination with COX inhibitors is taken on demand prior to expected sexual intercourse.
-
公开(公告)号：US10905667B2
公开(公告)日：2021-02-02
申请号：US16043567
申请日：2018-07-24
发明人： Anke Stroyer , Carmen Lobback , Peter Serno , Philipp Rubenbauer , Kai Lovis , Heiko Schirmer , Danja Grossbach , Donald Bierer , Britta Olenik , Tia Jacobs , Julia Küsel
IPC分类号： A61K31/00 , A61K9/00 , A61K47/00 , A61P9/10 , A61P25/28 , A61K31/192 , A61K9/20 , A61K47/10 , A61K47/38 , A61K45/06 , A61P13/00
摘要： The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
-
公开(公告)号：US20200030270A1
公开(公告)日：2020-01-30
申请号：US16043567
申请日：2018-07-24
发明人： Anke Stroyer , Carmen Lobback , Peter Serno , Philipp Rubenbauer , Kai Lovis , Heiko Schirmer , Danja Grossbach , Donald Bierer , Britta Olenik , Tia Jacobs , Julia Kusel
摘要： The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
-
6.发明授权Use and application regimen of a pharmaceutical composition containing levonorgestrel and a COX inhibitor for on-demand contraception 有权含有左炔诺孕酮和COX抑制剂的药物组合物的用途和应用方案用于按需避孕公开(公告)号：US09579330B2
公开(公告)日：2017-02-28
申请号：US14647740
申请日：2013-11-19
IPC分类号： A61K31/567 , A61K9/20 , A61K31/18 , A61K31/192 , A61K31/196 , A61K31/405 , A61K31/5415
CPC分类号： A61K31/567 , A61K9/20 , A61K31/18 , A61K31/192 , A61K31/196 , A61K31/405 , A61K31/5415 , A61K2300/00
摘要： The invention relates to a method of hormonal female controlled “on demand” contraception, in which a pharmaceutical preparation comprising a COX inhibitor and levonorgestrel is taken on demand prior to expected sexual intercourse. Further subjects of the invention relate to pharmaceutical compositions and application regimes for “on demand” contraception.
摘要翻译： 本发明涉及一种荷尔蒙女性控制的“按需”避孕方法，其中包括COX抑制剂和左炔诺孕酮的药物制剂在预期的性交前是按要求进行的。 本发明的其它主题涉及“按需”避孕的药物组合物和应用方案。
-
公开(公告)号：US11344519B2
公开(公告)日：2022-05-31
申请号：US17132765
申请日：2020-12-23
发明人： Anke Stroyer , Carmen Lobback , Peter Serno , Philipp Rubenbauer , Kai Lovis , Heiko Schirmer , Danja Grossbach , Donald Bierer , Britta Olenik , Tia Jacobs , Julia Küsel
IPC分类号： A61K31/00 , A61K9/00 , A61K31/192 , A61K9/20 , A61K47/10 , A61K47/38 , A61K45/06 , A61P25/28 , A61P13/00 , A61P9/10
摘要： The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising sodium (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoate and to processes for preparing the dosage forms and to their use for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal and pulmonary disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
-
公开(公告)号：US20210283046A1
公开(公告)日：2021-09-16
申请号：US17262491
申请日：2019-07-19
发明人： Anke Stroyer , Carmen Lobback , Peter Serno , Tia Jacobs
IPC分类号： A61K9/00 , A61K31/196 , A61K9/20 , A61K9/28
摘要： The present invention relates to orally administrable modified-release pharmaceutical dosage forms comprising (3S)-3-(4-chloro-3-{[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanoyl]amino}phenyl)-3-cyclopropylpropanoic acid and to processes for producing the dosage forms and to the use thereof for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of cardiac, renal, pulmonary and ophthalmological disorders, disorders of the central nervous system, fibrotic and inflammatory disorders and metabolic disorders.
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.02 秒)
